NGS as the First-line Treatment in Advanced Biliary Tract Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To evaluate disease objective response rate (ORR) of nivolumab in combination with
gemcitabine and TS1 in patients with advanced biliary tract cancer
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Kaohsiung Medical University Chung-Ho Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan